Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Atopic Dermatitis

Completed · Phase 2 · Has a placebo group

Conditions studied: Atopic Dermatitis

In brief

This Phase 2a trial will evaluate the effects of EP262 in subjects with atopic dermatitis

Key facts

Study ID

NCT06144424

Run by

Escient Pharmaceuticals, Inc

People needed

32

Starts

2023-10-25

Expected to finish

2024-07-31

Last updated by the study team

2025-08-24

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Clinically confirmed diagnosis of active atopic dermatitis for at least 1 year
• BSA of 3% to 20% and a vIGA-AD score of ≥3

You may not qualify if…

• Other active skin diseases associated with chronic pruritus
• Clinically infected atopic dermatitis that requires antibiotic therapy
• Use of specific treatments for atopic dermatitis

Where it is running

• Allervie Clinical Research — Birmingham, Alabama, United States
• RM Medical Research, Inc. — Miami Lakes, Florida, United States
• Indiana Clinical Trials Center — Plainfield, Indiana, United States
• Lawrence J. Green, MD LLC — Rockville, Maryland, United States
• Revival Research Institute, LLC — Troy, Michigan, United States
• Optima Research Boardman — Boardman, Ohio, United States
• J&S Studies, Inc. — College Station, Texas, United States
• Jordan Valley Dermatology Center — South Jordan, Utah, United States
• Dermatology Specialists of Spokane — Spokane, Washington, United States
• Innovaderm Research Inc. — Montreal, Quebec, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.